Holen Sie sich die Stockscreener-App
1.68
1.82%
0.03
Schlusskurs vom Vortag:
$1.65
Offen:
$1.64
24-Stunden-Volumen:
1.02M
Relative Volume:
0.46
Marktkapitalisierung:
$311.28M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-222.39M
KGV:
-1.2662
EPS:
-1.3268
Netto-Cashflow:
$-193.40M
1W Leistung:
+0.60%
1M Leistung:
+5.00%
6M Leistung:
-24.32%
1J Leistung:
+58.49%
1-Tages-Spanne:
$1.575
$1.71
1-Wochen-Bereich:
$1.57
$1.845
52-Wochen-Spanne:
$0.8302
$3.65
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Firmenname
Neumora Therapeutics Inc
Sektor
Branche
Telefon
(857) 760-0900
Adresse
260 ARSENAL PLACE, SUITE 1, WATERTOWN
Compare NMRA vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
1.68 | 311.28M | 0 | -222.39M | -193.40M | -1.3268 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-17 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2026-01-12 | Eingeleitet | Leerink Partners | Outperform |
| 2025-12-01 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-10-27 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-09-16 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2025-04-02 | Herabstufung | BofA Securities | Buy → Underperform |
| 2025-03-10 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2025-03-07 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-07 | Herabstufung | Stifel | Buy → Hold |
| 2025-01-02 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-05 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2024-10-01 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-07-22 | Eingeleitet | Needham | Buy |
| 2024-07-08 | Eingeleitet | Mizuho | Outperform |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-10 | Eingeleitet | BofA Securities | Buy |
| 2023-10-10 | Eingeleitet | Guggenheim | Buy |
| 2023-10-10 | Eingeleitet | JP Morgan | Overweight |
| 2023-10-10 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-10-10 | Eingeleitet | Stifel | Buy |
| 2023-10-10 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Neumora Therapeutics Inc Aktie (NMRA) Neueste Nachrichten
Neumora Therapeutics (NMRA) Edges Higher Amid Modest Gains, Holds Near Key SupportPut Flow Alert - dars.gov.et
Why Neumora Therapeutics, Inc. (NMRA) Is One of the Best Get Rich Quick Stocks to Buy - Yahoo Finance
5 Best Get Rich Quick Stocks to Buy Right Now - Insider Monkey
Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell 2000 Index - marketscreener.com
Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell 2500 Growth Benchmark - marketscreener.com
Neumora Therapeutics, Inc.(NasdaqGS:NMRA) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell 2000 Growth Benchmark - marketscreener.com
Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell 3000E Growth Benchmark - marketscreener.com
Neumora Therapeutics, Inc.(NasdaqGS: NMRA) added to Russell Microcap Index - marketscreener.com
Neumora Therapeutics, Inc.(NasdaqGS:NMRA) added to Russell Small Cap Completeness Index - marketscreener.com
Neumora Therapeutics Inc (NMRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Levi & Korsinsky Notifies Neumora Therapeutics, Inc. Investors of - The National Law Review
NMRA Slides As Neumora Kills Navacaprant After Phase 3 Blowup - StocksToTrade
NMRA Stock Drops As Neumora Axes Failed Depression Drug - timothysykes.com
NMRA IMPORTANT DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Neumora Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 7 Deadline in Securities Class Action First Filed by the - TMX Newsfile
Price to book forward of Neumora Therapeutics, Inc. – NASDAQ:NMRA - TradingView
NMRA Slides As Neumora Axes Navacaprant After Phase 3 Failure - timothysykes.com
Price to sales forward of Neumora Therapeutics, Inc. – NASDAQ:NMRA - TradingView
Enterprise value to EBIT forward of Neumora Therapeutics, Inc. – NASDAQ:NMRA - TradingView
Price to earnings forward of Neumora Therapeutics, Inc. – NASDAQ:NMRA - TradingView
Price to sales forward of Neumora Therapeutics, Inc. – BOATS:NMRA - TradingView
Enterprise value to EBITDA forward of Neumora Therapeutics, Inc. – BOATS:NMRA - TradingView
Price to earnings forward of Neumora Therapeutics, Inc. – BOATS:NMRA - TradingView
Enterprise value to revenue forward of Neumora Therapeutics, Inc. – BOATS:NMRA - TradingView
Neumora Therapeutics, Inc. Actuals & Estimates (NASDAQ:NMRA) - TradingView
NMRA Forecast — Price Target — Prediction for 2027 - TradingView
NMRA Stock On Track For Worst Day In 1.5 Years — Neumora Therapeutics' Lead Depression Drug Fails Late Stage Trials - Stocktwits
Neumora stock plunges 49% after late-stage depression drug failure - MSN
Mizuho Securities Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Neumora stock price target lowered to $4 by Mizuho on trial failure - Investing.com
Neumora Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds - The National Law Review
Neumora Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Pinto Joshua - Moomoo
Neumora Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Aurora Daljit Singh - Moomoo
Neumora Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plansmoomoo - Moomoo
Neumora Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer BERNS PAUL L - Moomoo
NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics (NMRA) for Potential Securities Fraud - Business Wire
Mizuho Securities Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Cuts Target Price to $4 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Rx Rundown: Sanofi, Neumora Therapeutics, Uniqure and more - Medical Marketing and Media
Neumora Therapeutics Inc (NMRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Neumora Therapeutics Inc (NMRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Neumora Therapeutics Inc (NMRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Robbins LLP Reminds Neumora Therapeutics, Inc. (NMRA) Investors - GuruFocus
NMRA Investor Alert: Levi & Korsinsky Investigates Neumora Therapeutics, Inc. (NMRA) for Potential Securities Fraud - ACCESS Newswire
Why Neumora Therapeutics (NMRA) Faces a Major Catalyst From Navacaprant’s Upcoming Depression Data - Yahoo Finance
NMRA SHAREHOLDER INVESTIGATION: SueWallSt Investigates Neumora Therapeutics for Possible Securities Law Violations – Company AnnouncementFT.com - Financial Times
Needham Maintains Neumora Therapeutics(NMRA.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Neumora Therapeutics Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics (NMRA) - PR Newswire
Neumora Therapeutics, Inc. Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Neumora Therapeutics, Inc. (NMRA) - ACCESS Newswire
Kappa Opioid Antidepressant Navacaprant Goes 0-for-3 in Phase 3: Neumora Cuts 35% of Staff - Tech Times
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Finanzdaten der Neumora Therapeutics Inc-Aktie (NMRA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Neumora Therapeutics Inc-Aktie (NMRA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Pinto Joshua | President |
Feb 17 '26 |
Sale |
3.54 |
5,967 |
21,093 |
57,783 |
| BERNS PAUL L | See Remarks |
Feb 17 '26 |
Sale |
3.51 |
9,819 |
34,459 |
7,395,185 |
| Milligan Michael Lee | See Remarks |
Feb 17 '26 |
Sale |
3.56 |
1,436 |
5,119 |
21,034 |
2.64%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):